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Background: a beneficial effect of rituximab on Focal Segmental 
Glomerulosclerosis (FSGS) in pediatric patients or in transplant recipients has 
been reported in isolated cases. However, the use of Rituximab in adult patients 
with idiopathic FSGS needs further investigation. 
Methods: Eight patients who had biopsy-proven FSGS (63.9±14.0, range 40-81 
yr, 4 women, 4 men) with major risk factors precluding corticosteroids or 
conventional immunosuppression were treated with high dose of rituximab (8 
weekly doses of 375mg/m2) and prospectively followed up for at least 2 years 
(29.1 ± 8.8 mo, range 24 to 42 mo).  
Results: Rituximab failed to improve proteinuria in seven out of 8 patients, who 
had persistent nephrotic proteinuria.  In one case, a rapidly deteriorating renal 
function was also observed. Only one patient showed an improvement of renal 
function and a remarkable proteinuria reduction. There were no differences in 
clinical or laboratory characteristics or in the CD20 B lymphocyte count after 
rituximab between the responder and the 7 non responders patients.  
Conclusions: Only a minority (one of eight) in our series of adult patients with 
FSGS showed positive effects of high doses of rituximab. Future studies are 
warranted to investigate more promising therapeutic options in the 
management of FSGS.  
Introduction 
 
Focal segmental glomerulosclerosis (FSGS) is a common cause of nephrotic 
syndrome in children and in adults. More than 60% of patients treated with 
steroids achieve remission [1]. However, among those achieving remission 
(either complete or partial), approximately half of them experience relapses [2]. 
In patients with frequent relapses or steroid dependency, co-morbidities 
secondary to steroid treatment may be challenging and deeply impacting in 
prognosis and quality of life [3]. Long-term complications of steroid regimens, 
such as impaired glucose tolerance, hypertension, osteopenia/osteoporosis, 
dyslipidemia, and an increased risk of infections and cardiovascular events are 
common. Steroid-sparing agents such as cyclosporine A, mycophenolate mofetil, 
azathioprine, tacrolimus, levamisole, cyclophosphamide and chlorambucil have 
been investigated in FSGS as second- and third-line treatment [4–8], but adverse 
events and toxicities attributed to these immunosuppressants also limit their 
long-term use. 
Rituximab (RTX) is a chimeric monoclonal antibody directed against CD20 
positive B-cells, and is a part of the therapeutic option in diseases like 
rheumatoid arthritis [9] and ANCA-associated vasculitis [10]. Moreover, RTX is a 
valuable option in the treatment of several connective tissue diseases [11–13] 
and immune meditated glomerular diseases as idiopathic membranous 
nephropathy (IMN) [14,15] and Henoch-Schonlein purpura nephritis [16]. RTX 
has emerged as an alternative treatment of childhood frequently relapsing, 
steroid-dependent or steroid-resistant nephrotic syndrome [17–20]. A beneficial 
effect of rituximab on FSGS in pediatric patients or in transplant recipients has 
been shown in isolated reports and few case series [21–23]. However, in adult 
patients with FSGS with persisting nephrotic syndrome, data on the efficacy of 
RTX treatment are still elusive [24,25].  
 
Methods: 
Consecutive patients meeting the following criteria were prospectively enrolled 
in our study: (1) biopsy-proven FSGS; (2) nephrotic syndrome; (3) absence of 
concomitant infections, comorbid conditions, or systemic diseases that could 
have a pathogenic relationship with the nephrotic syndrome; and (4) presence of 
major risk factors precluding the use of corticosteroids. For each patient, the 
following data were extracted from patient records: demographic 
characteristics, clinical data (elevated blood pressure -BP, body weight, edema), 
time elapsed since the diagnosis of FSGS by renal biopsy. Any non-specific 
antiproteinuric treatment before rituximab administration were also recorded. A 
careful analysis of familial history of renal diseases was performed in every case. 
The pathologic variant of FSGS (collapsing, tip lesion, cellular variant, perihilar, 
and FSGS not otherwise specified) was recorded, as well as the percentage of 
glomeruli showing a global sclerosis. The severity of tubulointerstitial fibrosis 
was graded as absent (0), mild (+), moderate (++), and severe (+++). 
For all patients, the following clinical and laboratory parameters were recorded 
at baseline (onset of rituximab administration), monthly during the treatment 
period, and then every 3 to 6 mo after treatment: BP, body weight, complete 
blood counts, electrolytes, and routine serum biochemistry profile (including 
total proteins, albumin, a lipid panel, and serum creatinine). Creatinine clearance 
and proteinuria were measured by 24-h urine collections at each time point. For 
all patients, B-cell flow-cytometry was performed after every rituximab 
treatment. For comparison of variables at baseline and follow-up, Student’s t-test 
was used for normally distributed parameters, and the non-parametric Mann-
Whitney test for non-normally distributed parameters. Correlations were 
calculated and significance determined by Fisher’s test. For these analyses, with 
SPSS (IBM Corporation, NY, USA) software programs was used. p<0.05 was 
considered significant. 
Rituximab Protocol:  
Rituximab was given at high dose in 8 weekly infusions of 375 mg/m2. This 
scheme was chosen when analyzing available literature about the use of 
Rituximab in adult patients with FSGF. In their report, Fernandez-Fresnedo G 
and cow-workers showed that that the only three out of eight patients who had a 
positive response to Rituximab had received more rituximab doses (e.g. eight 
infusions of 375 mg/m2 ) than the other five patients, in whom four weekly 
intravenous infusions of 375 mg/m2 of rituximab had been administered [24].  
 
Results:  
Eight adult patients who had biopsy-proven primary FSGS received high dose of 
rituximab (8 weekly doses of 375 mg/m2) and were prospectively enrolled in 
our study. The main demographic and clinical characteristics of the patients are 
summarized in Table 1. Patients were 4 women and 4 men, with a mean age of 
63.9±14.0 (range 40-81 yrs) and a mean disease duration of 3 ± 3 mo (range 1 to 
6 mo). All patient had major risk factors precluding corticosteroid regimens; in 
details, all the patients had elevated BP, 4 were diabetic (patients #1,4,6,7), 3 
were older than 70 yrs (patients#3,6,7), 3 had  osteopenia (patients#3,6,7,).   
All patients had marked proteinuria at the time of rituximab treatment (mean 
proteinuria 5.3 ± 1.9 g/24 h; range 3.6 to 8.0 g/24 h), and their mean serum 
creatinine was 2.6 ± 1.2 mg/dl (range 0.9 to 3.7 mg/dl). Supportive treatments of 
nephrotic syndrome (including diuretics, statins, angiotensin-converting enzyme 
inhibitors, or angiotensin receptor blockers) given at the time of rituximab 
administration were maintained during follow-up.  
Renal biopsies characteristics are specified in Table 2. The percentage of globally 
sclerosed glomeruli ranged from 10 to 40%. Interstitial fibrosis was absent in 
two cases, mild in four, and moderate in two. No correlation between histologic 
features and response to rituximab treatment was found. 
The tolerance to rituximab infusion was good, and no adverse effects were 
observed during the period of rituximab administration or during the follow-up. 
The mean duration of follow-up after rituximab therapy was 29.1 ± 8.8 mo 
(range 24 to 42 mo). 
As shown in Figure 1, rituximab failed to resolve nephrotic syndrome in most of 
the patients. Patients #1,#4,#5 persisted with a massive proteinuria and a 
roughly stable high serum creatinine. Patients #5 showed a clear worsening of 
renal function accompanied by a persistent massive proteinuria. Patient #6 and 
7 #, who had clearly impaired renal function at baseline (serum creatinine 2.8 
and 3.5 mg/dl), showed a marginal non-significant proteinuria decrease after the 
rituximab course. Patient #8 presented with conserved renal function and her 
proteinura remained stable after 24th of follow-up.  
Only one patients (patient #3) experienced a sustained improvement. She 
presented with severe proteinuria and deteriorated renal function at the time of 
rituximab administration (proteinuria 7 g/24 h and serum creatinine 3.7 mg/dl, 
respectively) and showed a clear proteinuria decrease to non-nephrotic values 
(1.5 g/24 h) accompanied by a slight improvement of renal function (Table 1).  
In the whole group of patients, we failed to observe a significant decrease in 
proteinuria levels (5.3 ± 1.9 g/24 h at baseline to 3.9 ± 1.8 g/24 h at the end of 
follow-up, and serum creatinine increased from 2.6 ± 1.2 to 3.5 ± 2.5 mg/dl (NS). 
CD20+ B lymphocytes decreased to undetectable levels after the first course of 
rituximab in all the patients. Time to recover a normal CD20+ count after 
rituximab treatment ranged between 9 and 25 mo (12.5 ± 5.6 mo) as shown in 
Figure 2. No differences in the CD20+ B lymphocyte profile has been observed in 
the patient with a positive response to rituximab treatment (patients #7).  
 
Discussion 
Some case reports and observational studies have created a considerable 
expectation about the therapeutic possibilities of rituximab in nephrotic 
syndrome [17,18]. Uncontrolled studies have shown significant proteinuria 
decrease after rituximab treatment in patients with idiopathic membranous 
nephropathy [14,26]. Conversely, several case reports in pediatric patients on in 
transplant suggested that rituximab could be a potentially effective and safe 
alternative in FSGS [27–29]. 
The possibility of a beneficial effect of rituximab on primary FSGS was initially 
suggested by the publication of cases who had recurrent FSGS in renal grafts and 
had remission of nephrotic syndrome after treatment with rituximab. To date, a 
very limited number of adult patients with FSGS has been successfully treated 
RTX [30–34]. Some of these patients were treated with rituximab because of the 
development of lymphoproliferative disorders [30,32], suggesting a possible 
pathogenic relationship between such hematologic disorder and the 
pathogenesis of proteinuria. Conversely, two other reports, including six patients 
(four adults, two children) showed a failure of rituximab to improve nephrotic 
syndrome in renal transplant patients with recurrent FSGS [35,36].  
To date, six reports including overall 10 children or adolescents who had 
primary FSGS in their native kidneys were treated with rituximab [27–29,37,38]. 
All of them had a positive response, achieving complete or partial remission of 
nephrotic syndrome, although, in some cases, rituximab was administered when 
proteinuria was in non-nephrotic values.  
Fernandez-Fresnedo and co-workers, who showed a poor efficacy of rituximab 
in adult patients with severe nephrotic syndrome. In their cohort, 5 of eight 
patients continued to show massive nephrotic proteinuria, and renal function 
exhibited a rapid deterioration on follow-up in two of them; however, two other 
patients, who had a very poor renal prognosis (massive proteinuria 
accompanied by increasing serum creatinine), showed a partial improvement of 
renal function accompanied by a remarkable reduction in proteinuria [24]. The 
remaining patient, who received two rituximab courses, showed a clear 
proteinuria reduction after every rituximab treatment, but this beneficial effect 
was only transitory [24].  
In our cohort, one of largest of adult patients the longest follow up ever reported, 
no significant decrease in proteinuria levels paralleled with a substantial 
increase in serum creatinine was observed. Only one patient had a reduction of 
about 80% of baseline value of proteinuria.  
The reasons why RTX seems to be effective in pediatric patients with primary 
FSGS or in transplant recipients whereas it fails to induce any improvement in 
adult patients with idiopathic FSGF remain unknown. The present cohort had 
some peculiarities. First, our patients sample included adult cases with definite 
contraindication to corticosteroids and recent onset of disease. Second, RTX was 
used as a first line treatment on naïve patients.  Third, our patients received very 
high doses of RTX and the CD20+ B cells profile excluded any possibilities of 
hematologic resistance or developing of neutralizing anti-chimeric antibodies. 
This study including one of the largest cohort of adults patients with idiopathic 
FSGS with the longest follow-up, showed that despite the administration of the 
high dose of RTX, and no definite benefit in terms of proteinuria or renal function 
could be observed, and definitely raised the question of ethical justification of 
treating patients with adult onset FSGS with RTX.     
Conversely, our study suffers for some limitations. While reflecting a real word 
scenario, the presence of several co-morbidities precluding the use 
corticosteroids (e.g. diabetes, high blood pressure) might have resulted in the 
substantial heterogeneity in biopsy findings at electronic microscopy. A 
beneficial role for Rituximab in a restricted cohort homogeneous for widespread 
foot process effacement at electronic microscopy  cannot be ruled out. 
 
Conclusions 
Our results do not support the promising effects initially reported with 
rituximab in adults with FSGS.  Among eight adult patients who had nephrotic 
proteinuria, only one patient showed a sustained positive response, with a 
reduction of 80% of baseline of proteinuria value. More studies are necessary to 
further characterize the FSGS patients who could benefit from RTX.  
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Table 1: Demographic and clinical characteristics of the patients with FGSG 
treated with Rituximab.  
 
Table 2: Biopsy characteristics of the patients with FGSG treated with Rituximab.  
Figure 1:  Evolution of serum creatinine (panel A) and proteinuria (panel B) after 
rituximab therapy.  
Figure 2:  Circulating B cells at the time of rituximab administration (day 0) and 
at different time points thereafter 
 
